Biopharma Private Placement Insights (Q2'23 and FY'22)

Oppenheimer & Co. Inc. July 13, 2023

The latest edition of Oppenheimer & Co. Inc.’s Quarterly Biopharma Private Placement Insights Report is now available upon request.

Key Takeaways:

Private markets continue to weather the storm and remain remarkably resilient in 1H 2023
  • Median quarterly deal volume ($4.4B) tracking above pre‐pandemic median ($3.2B) and tracking evenly with 2022 quarterly median ($4.4B)
  • Median quarterly deal counts remain robust vs pre-pandemic (~74 vs 66 deals / quarter ) and are tracking slightly below 2022 quarterly medians
  • While Series B rounds have drawn the majority of funding from investors in 1H 2023, Series A funding is roughly on par
  • Pre‐ / post‐money valuations for Series A rounds have rebounded in Q2 2023, while Bs have remained solid and C valuations have declined over LTM
  • While deal sizes are similar regardless of clinical stage, pre‐$ valuations tend to be higher for companies with later stage assets
  • Oncology attracted the largest share of VC dollars in 1H 2023 while I&I and Autoimmunity spaces continue to gain market share
  • Small molecules, cell & gene therapies, and antibodies accounted for 31%, 21% and 19% of all deals in Q2 2023, respectively
  • New investors led 76%, 60%, and 40% of Series A, Series B, and Series C+ rounds in 1H 2023, respectively
  • Co-led syndicates featuring new and existing investors made up 8%, 20%, and 7% of Series A, Series B, and Series C+ rounds in 1H 2023, respectively
  • Over 60% of private rounds were raised by preclinical‐stage companies in Q2 2023

Please reach out to Michael Margolis, R.Ph. ([email protected]), Daniel Parisotto, PhD ([email protected]), Dylan Gering ([email protected]), or Culver Duquette ([email protected]) directly to request a copy.

Michael Margolis
Name:

Michael A. Margolis, R.Ph.

Title:

Senior Managing Director, Co-Head of Healthcare, Head of Healthcare Life Sciences

DISCLOSURES

This notice is provided for informational purposes only, and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.

This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.

2023 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 5803899.1